This is the authors' abstract. We don't add key points for this paper.
Three-dimensional (3D) liver models provide increased physiological relevance for evaluating chemical toxicity; however, their suitability for assessing co-exposure effects remains underexplored. This study investigated the impact of co-exposure to individually sub-cytotoxic concentrations of pharmaceuticals and biopolymers in HepG2-derived 3D spheroids using multiparametric endpoints. HepG2 spheroids (∼800 cells/spheroid) were generated in ultra-low attachment 96-well plates and cultured for 5 days to reach functional steady state. Spheroids were then exposed for 48 h to rifampicin, tamoxifen, epsilon poly-L-lysine (ePL), hyaluronan (Hya), and poly-L-arginine (PAR). sub-cytotoxic concentrations were determined using 3D viability assays and applied for co-exposure studies. The following combinations were evaluated: rifampicin + tamoxifen, Hya + ePL, Hya + PAR, and ePL + PAR. Endpoints assessed included spheroid growth dynamics, viability, CYP3A4 activity, and levels of hepatic biomarkers (LDH, AST, urea and transferrin). Rifampicin-tamoxifen co-exposure increased spheroid size without affecting metabolic activity, CYP3A4, or most biomarkers, although AST was elevated, suggesting sub-cytotoxic hepatocellular stress. In contrast, Hya-ePL and ePL-PAR induced spheroid compaction and reduced metabolic activity, accompanied by increased CYP3A4 activity, indicating modulation of xenobiotic metabolism. Hya-ePL also reduced LDH and trended toward lower urea levels, suggesting altered hepatocellular turnover and urea cycle activity without overt cytotoxicity. Hya-PAR exposure did not significantly affect any endpoint. Overall, co-exposure to individually sub-cytotoxic compounds induced subtle but mechanistically relevant morphological and functional alterations in 3D liver spheroids. These findings demonstrate that mixture effects cannot be predicted from single-compound data alone and highlight the importance of mixture toxicity assessment in physiologically relevant in vitro systems.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ghasemzadeh‐Hasankolaei et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: